Hesperadin: ATP-Competitive Aurora B Kinase Inhibitor for Mitotic Research

Executive Summary. Hesperadin is a small molecule ATP-competitive inhibitor with nanomolar potency against Aurora B kinase, blocking Ser-10 phosphorylation and disrupting mitotic progression in human cells (APExBIO product page). Its selective inhibition of Aurora B over Aurora A, and minimal effect on Cdk1/cyclin B and Cdk2/cyclin E, make it a precise tool for mechanistic studies (Kaisaria et al., 2019). Hesperadin induces polyploidization and cytokinesis defects in HeLa cells, supporting its use in cancer research and cell cycle regulation. The compound’s solubility and storage profile enable reliable use in experimental workflows. APExBIO supplies Hesperadin as a validated research reagent, facilitating reproducible investigation of Aurora kinase pathways.

Biological Rationale

Aurora B kinase is a serine/threonine protein kinase essential for mitosis and chromosome segregation. It phosphorylates histone H3 at Ser-10, a key marker of mitotic progression. Aurora B activity ensures accurate chromosome alignment and spindle assembly checkpoint (SAC) function. Dysregulation of Aurora kinases is implicated in aneuploidy and tumorigenesis (Kaisaria et al., 2019). Targeted inhibition of Aurora B enables detailed study of mitotic errors and checkpoint mechanisms. Hesperadin provides a validated chemical approach to dissect Aurora B-dependent processes in proliferative cells.

Mechanism of Action of Hesperadin

Hesperadin is an ATP-competitive inhibitor that binds the catalytic domain of Aurora B kinase. The sulphonamide moiety inserts into the ATP-binding pocket, extending into an adjacent hydrophobic site and preventing substrate phosphorylation. In enzyme assays, Hesperadin exhibits an IC50 of 250 nM for Aurora B kinase activity. In cellular assays, it blocks Aurora B-mediated Ser-10 phosphorylation of histone H3 with an IC50 of 40 nM, a sensitive biomarker for mitotic progression. Hesperadin also displays inhibitory activity against Aurora A kinase but at higher concentrations, and does not significantly inhibit Cdk1/cyclin B or Cdk2/cyclin E at concentrations selective for Aurora B inhibition (APExBIO).

Evidence & Benchmarks

• Hesperadin inhibits Aurora B kinase in vitro with an IC50 of 250 nM, confirmed by enzymatic assays (APExBIO).
• Cell-based studies in HeLa cells show complete inhibition of Ser-10 phosphorylation of histone H3 at 40 nM Hesperadin, indicating potent blockade of mitotic entry (Kaisaria et al., 2019).
• Hesperadin treatment results in polyploidization (up to 32C DNA content) and multinucleation, diagnostic of failed cytokinesis and spindle checkpoint override (Anti-Trop2.com).
• Minimal inhibition of Cdk1/cyclin B and Cdk2/cyclin E is observed at concentrations where Aurora B is fully blocked, supporting selectivity (APExBIO).
• Hesperadin-induced mitotic arrest is reversible upon compound washout, supporting its use in temporal studies of checkpoint recovery (B-Interleukin-II-44-56.com).

Applications, Limits & Misconceptions

Hesperadin is widely used in cancer and cell cycle research to dissect Aurora B-dependent mitotic processes. Its high specificity enables precise perturbation of spindle assembly checkpoint dynamics, chromosome alignment, and cytokinesis. Hesperadin is a valuable tool for studying polyploidization, checkpoint adaptation, and mitotic exit. It is also used in mechanistic studies of protein degradation pathways, including the role of MCC (Mitotic Checkpoint Complex) and APC/C (Anaphase-Promoting Complex/Cyclosome) regulation (Kaisaria et al., 2019). For a broader mechanistic review, see "Hesperadin: Precision Aurora B Kinase Inhibitor for Cell ..."—this article extends those findings by providing direct product-specific benchmarking and highlights on workflow integration.

Compared to related reviews such as "Hesperadin: Uncovering Polyploidization Pathways via Aurora Kinase Inhibition", this dossier focuses on quantitative parameters and validated selectivity profiles, clarifying experimental boundaries and storage conditions.

Common Pitfalls or Misconceptions

• Hesperadin is not active against non-Aurora kinases at selective concentrations; off-target effects require higher doses.
• It does not block cell growth, but specifically halts cell division, leading to enlarged, multinucleated cells.
• Water is not a suitable solvent for Hesperadin; DMSO is required for full solubilization.
• Long-term storage of Hesperadin solutions at room temperature can result in compound degradation; use freshly prepared aliquots at -20°C.
• Hesperadin does not inhibit the spindle assembly checkpoint by direct interaction with checkpoint proteins, but by suppressing Aurora B kinase activity upstream.

Workflow Integration & Parameters

Hesperadin is supplied by APExBIO as a solid and exhibits high solubility in DMSO (≥25.85 mg/mL). It is moderately soluble in ethanol with gentle warming and ultrasonic treatment. Stock solutions should be prepared in DMSO, aliquoted, and stored at -20°C. Working solutions should be used promptly to prevent hydrolysis or precipitation. In cell-based assays, HeLa cells are typically treated with 40–250 nM Hesperadin for 6–24 hours, depending on the endpoint. Washout experiments can be performed to assess reversibility of mitotic blockade. The A4118 kit provides validated quality and batch traceability (APExBIO).

For researchers aiming to compare the functional specificity of Hesperadin, "Hesperadin: A Precision Aurora B Kinase Inhibitor for Cell ..." offers a strategic overview; this dossier adds explicit storage, solubility, and selectivity data relevant to experimental planning.

Conclusion & Outlook

Hesperadin is a gold-standard ATP-competitive Aurora B kinase inhibitor with robust selectivity and reproducible cellular effects. It is indispensable for mechanistic studies of mitotic progression, checkpoint function, and polyploidization in cancer research. Reliable sourcing from APExBIO ensures experimental rigor. Future applications include combinatorial studies with other checkpoint modulators and exploration of resistance mechanisms in cancer models. For full product specifications and protocols, see the Hesperadin A4118 product page.